Clément Morgat

Publications

• Membrane and Nuclear Absorbed Doses from 177Lu and 161Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study
  Alexandre Larouze, Mario Alcocer-Ávila, Clément Morgat, Christophe Champion, Elif Hindié.
  J Nucl Med. 2023-06-15. : jnumed.123.265509.
  10.2967/jnumed.123.265509
• Modular One-Pot Strategy for the Synthesis of Heterobivalent Tracers
  Thibaud Bailly, Sacha Bodin, Victor Goncalves, Franck Denat, Clément Morgat, Aurélie Prignon, Ibai E. Valverde.
  ACS Med. Chem. Lett.. 2023-04-21.
  10.1021/acsmedchemlett.3c00057
• Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
  Romain Schollhammer, Marie-Laure Quintyn Ranty, Henri de Clermont Gallerande, Florine Cavelier, Ibai E. Valverde, Delphine Vimont, Elif Hindié, Clément Morgat.
  Cancers. 2023-04-18. 15(8) : 2345.
  10.3390/cancers15082345
• Design and preclinical evaluation of a novel apelin-based PET radiotracer targeting APJ receptor for molecular imaging of angiogenesis
  Béatrice Louis, Vincent Nail, Oriane Nachar, Ahlem Bouhlel, Anaïs Moyon, Laure Balasse, Stéphanie Simoncini, Adrien Chabert, Samantha Fernandez, Pauline Brige, Guillaume Hache, Aura Tintaru, Clément Morgat, Françoise Dignat-George, Philippe Garrigue, Benjamin Guillet.
  Angiogenesis. 2023-03-27.
  10.1007/s10456-023-09875-8
• A proof of principle study using radiopharmaceuticals to quantify and localize container-content interactions in medical syringes
  C. Dupire, P. Chennell, B. Pereira, N. Courtiol, S. Buj, R. Cueff, S. Crauste-Manciet, V. Sautou, C. Morgat.
  Sci Rep. 2023-02-15. 13(1)
  10.1038/s41598-023-29923-z
• Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2
  Sacha Bodin, Santo Previti, Emmanuelle Jestin, Delphine Vimont, Imade Ait-Arsa, Frédéric Lamare, Emmanuelle Rémond, Elif Hindié, Florine Cavelier, Clément Morgat.
  ACS Omega. 2023-02-10. 8(7) : 6994-7004.
  10.1021/acsomega.2c07814
• Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study
  Romain Schollhammer, Grégoire Robert, Julien Asselineau, Mokrane Yacoub, Delphine Vimont, Nicolas Balamoutoff, Franck Bladou, Antoine Bénard, Elif Hindié, Henri H de Clermont-Gallerande, Clément Morgat.
  J Nucl Med. 2022-09-02. : jnumed.122.263889.
  10.2967/jnumed.122.263889
• Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors
  Clément Morgat, Véronique Brouste, Adrien Chastel, Valérie Vélasco, Gaétan Macgrogan, Elif Hindié.
  Breast Cancer Res Treat. 2021-10-01.
  10.1007/s10549-021-06402-5
• ⁶⁸Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of (68Ga)Ga-RM2
  Adrien Chastel, Delphine Vimont, Stephane Claverol, Marion Zerna, Sacha Bodin, Mathias Berndt, Stéphane Chaignepain, Elif Hindié, Clément Morgat.
  Pharmaceutics. 2021-07-28. 13(8) : 1160.
  10.3390/pharmaceutics13081160
• In vitro and pilot in vivo imaging of 18 kDa translocator protein (TSPO) in inflammatory vascular disease.
  Romain Schollhammer, Sébastien Lepreux, Nicole Barthe, Delphine Vimont, Anne Rullier, Igor Sibon, Xavier Berard, Andrea Zhang, Yasuyuki Kimura, Masahiro Fujita, Robert B. Innis, Paolo Zanotti-Fregonara, Clément Morgat.
  EJNMMI Res. 2021-05-05. 11(1)
  10.1186/s13550-021-00786-7
• Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging
  Roberto Fanelli, Adrien Chastel, Santo Previti, Elif Hindié, Delphine Vimont, Paolo Zanotti-Fregonara, Philippe Fernandez, Philippe Garrigue, Frédéric Lamare, Romain Schollhammer, Laure Balasse, Benjamin Guillet, Emmanuelle Rémond, Clément Morgat, Florine Cavelier.
  Bioconjugate Chem.. 2020-09-18.
  10.1021/acs.bioconjchem.0c00419
• 68Ga-PSMA-617 compared with 68Ga-RM2 and 18F-FCholine PET/CT for the initial staging of high-risk prostate cancer
  .
  . .
  10.1097/RLU0000000000002672
• Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
  Mario E. Alcocer-Ávila, Aymeric Ferreira, Michele A. Quinto, Clément Morgat, Elif Hindié, Christophe Champion.
  EJNMMI Phys. 2020-05-19. 7(1)
  10.1186/s40658-020-00301-2
• Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides
  Adrien Chastel, Dennis J. Worm, Isabel D. Alves, Delphine Vimont, Melina Petrel, Samantha Fernandez, Philippe Garrigue, Philippe Fernandez, Elif Hindié, Annette G. Beck-Sickinger, Clément Morgat.
  EJNMMI Res. 2020-03-02. 10(1)
  10.1186/s13550-020-0612-8
• Étude dosimétrique de préparations de médicaments radiopharmaceutiques au 68Ga
  C. Morgat, D. Vimont, E. Hindié, P. Fernandez, S. Buj.
  Médecine Nucléaire. 2019-10-01. 43(5-6) : 381-385.
  10.1016/j.mednuc.2019.04.007
• 68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer
  Romain Schollhammer, Henri de Clermont Gallerande, Grégoire Robert, Mokrane Yacoub, Delphine Vimont, Elif Hindié, Philippe Fernandez, Clément Morgat.
  Clinical Nuclear Medicine. 2019-09-01. 44(9) : e535-e536.
  10.1097/rlu.0000000000002672
• Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
  Romain Schollhammer, Henri De Clermont Gallerande, Mokrane Yacoub, Marie-Laure Quintyn Ranty, Nicole Barthe, Delphine Vimont, Elif Hindié, Philippe Fernandez, Clément Morgat.
  EJNMMI Res. 2019-06-03. 9(1)
  10.1186/s13550-019-0517-6
• Early use of abiraterone and radium-223 in metastatic prostate cancer
  Elif Hindié, Clément Morgat.
  The Lancet Oncology. 2019-05-01. 20(5) : e229.
  10.1016/s1470-2045(19)30235-9
• Radiopharmaceuticals targeting PSMA for imaging and/or therapy
  C. Morgat.
  Médecine Nucléaire. 2019-05-01. 43(3) : 284-286.
  10.1016/j.mednuc.2019.04.003
• Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases
  Clément Morgat, Adrien Chastel, Vincent Molinie, Romain Schollhammer, Gaétan Macgrogan, Valérie Vélasco, Bernard Malavaud, Philippe Fernandez, Elif Hindié.
  IJMS. 2019-04-07. 20(7) : 1721.
  10.3390/ijms20071721
• Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples
  Clément Morgat, Romain Schollhammer, Gaétan Macgrogan, Nicole Barthe, Valérie Vélasco, Delphine Vimont, Anne-Laure Cazeau, Philippe Fernandez, Elif Hindié.
  PLoS ONE. 2019-01-15. 14(1) : e0210905.
  10.1371/journal.pone.0210905
• État actuel de l’utilisation en essais cliniques de molécules radiomarquées au 68Ga en France. Exemple du site de Bordeaux
  C. Morgat, D. Vimont, H. de Clermont Gallerande, J. Mazère, F. Xuereb, L. Bordenave, E. Hindié, P. Fernandez.
  Médecine Nucléaire. 2018-11-01. 42(6) : 428-431.
  10.1016/j.mednuc.2018.08.003
• Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists
  Elif Hindié, Clément Morgat, Paolo Zanotti-Fregonara, Magalie Haissaguerre, Laurence Bordenave, Antoine Tabarin.
  J Nucl Med. 2017-10-06. 59(3) : 546-547.
  10.2967/jnumed.117.202630
• Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors
  Elif Hindié, Paolo Zanotti-Fregonara, Clément Morgat.
  J Nucl Med. 2017-08-17. 59(3) : 544-544.
  10.2967/jnumed.117.199158
• Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
  Paolo Zanotti-Fregonara, Clément Morgat, Christophe Champion, Elif Hindié.
  Eur J Nucl Med Mol Imaging. 2017-03-10. 44(6) : 1095-1096.
  10.1007/s00259-017-3667-7
• Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
  Clément Morgat, Gaétan MacGrogan, Véronique Brouste, Valérie Vélasco, Nicolas Sévenet, Hervé Bonnefoi, Philippe Fernandez, Marc Debled, Elif Hindié.
  J Nucl Med. 2017-03-09. 58(9) : 1401-1407.
  10.2967/jnumed.116.188011
• Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy
  E. Hindie, P. Zanotti-Fregonara, M. A. Quinto, C. Morgat, C. Champion.
  Journal of Nuclear Medicine. 2016-02-09. 57(5) : 759-764.
  10.2967/jnumed.115.170423
• Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1
  Clément Morgat, Fritz-Line Vélayoudom-Céphise, Paul Schwartz, Martine Guyot, Delphine Gaye, Delphine Vimont, Jürgen Schulz, Joachim Mazère, Marie-Laure Nunes, Denis Smith, Elif Hindié, Philippe Fernandez, Antoine Tabarin.
  Eur J Nucl Med Mol Imaging. 2016-01-28. 43(7) : 1258-1266.
  10.1007/s00259-016-3319-3
• Comparison between Three Promising ß-emitting Radionuclides, 67Cu, 47Sc and 161Tb, with Emphasis on Doses Delivered to Minimal Residual Disease
  Christophe Champion, Michele A. Quinto, Clément Morgat, Paolo Zanotti-Fregonara, Elif Hindié.
  Theranostics. 2016-01-01. 6(10) : 1611-1618.
  10.7150/thno.15132
• A phantom-based method to standardize dose-calibrators for new β+-emitters
  Clément Morgat, Joachim Mazère, Philippe Fernandez, Sébastien Buj, Delphine Vimont, Jürgen Schulz, Frédéric Lamare.
  Nuclear Medicine Communications. 2015-02-01. 36(2) : 201-206.
  10.1097/mnm.0000000000000227
• Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors
  C. Morgat, A. K. Mishra, R. Varshney, M. Allard, P. Fernandez, E. Hindie.
  Journal of Nuclear Medicine. 2014-09-04. 55(10) : 1650-1657.
  10.2967/jnumed.114.142000
• Gallium-68: Chemistry and Radiolabeled Peptides Exploring Different Oncogenic Pathways
  Clément Morgat, Elif Hindié, Anil K. Mishra, Michèle Allard, Philippe Fernandez.
  Cancer Biotherapy and Radiopharmaceuticals. 2013-03-01. 28(2) : 85-97.
  10.1089/cbr.2012.1244